Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 60/100

Failure Rate

12.5%

1 terminated/withdrawn out of 8 trials

Success Rate

83.3%

-3.2% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 5 completed trials have results

Key Signals

2 recruiting

Enrollment Performance

Analytics

Phase 1
4(50.0%)
Phase 2
4(50.0%)
8Total
Phase 1(4)
Phase 2(4)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (8)

Showing 8 of 8 trials
NCT07296484Phase 2Recruiting

Trial Against INtractable Type 2 Diabetes (CAPTAIN-T2D)

Role: lead

NCT05436639Phase 2Completed

SPI-62 as a Treatment for Hypercortisolism Related to a Benign Adrenal Tumor

Role: lead

NCT07226635Phase 1Completed

Pharmacokinetic Interaction Trial of Clofutriben With Midazolam and Prednisolone

Role: lead

NCT07227922Phase 1Recruiting

Clofutriben Pharmacokinetics in Patients With Impaired Renal Function

Role: lead

NCT05307328Phase 2Completed

SPI-62 as a Treatment for Adrenocorticotropic Hormone-dependent Cushing's Syndrome

Role: lead

NCT06281236Phase 1Terminated

A Trial of Prednisolone in Combination With SPI-62 in Participants With Polymyalgia Rheumatica (PMR)

Role: lead

NCT05436652Phase 2Completed

A Trial of Prednisolone in Combination With SPI-62 or Placebo in Subjects With Polymyalgia Rheumatica (PMR)

Role: lead

NCT05409027Phase 1Completed

A Study to Assess 11 Beta-hydroxysteroid Dehydrogenase Type 1 Inhibition in Adipose Tissue by SPI-62

Role: lead

All 8 trials loaded